跳至主要内容
临床试验/NCT03678818
NCT03678818已完成不适用

Latrunculin A Supplementation to ICSI Handling Medium

Ibn Sina Hospital2 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2018年9月25日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
300
试验地点
2
主要终点
oocyte survival rate

研究概览

简要总结

Vienna Consensus has identified 10% damage rate after ICSI as a competency value. Despite the highest quality embryologists doing ICSI, degeneration sometimes occurs due to oocyte factors such as the fragile membrane, etc. Latrunculin A serves to facilitate spindle or pronuclear transfer procedures helping to reduce the damage rate with no harm reported. Using Latrunculin A during ICSI could serve to rescue some oocytes from the degeneration allowing for more chances of viable zygotes,

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 42 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • ICSI participants

排除标准

  • 未提供

研究组 & 干预措施

Handling Medium Supplemented with Latrunculin A

Experimental

干预措施: Medium Supplemented with Latrunculin A (Other)

Handling Medium as it is.

No Intervention

结局指标

主要结局

oocyte survival rate

时间窗: 6 days of culture

次要结局

  • fertilization rate(6 days of culture)
  • Blastocyst formation rate(6 days of culture)
  • Blastocyst quality rate(6 days of culture)
  • Clinical pregnancy rate(three months)
  • Implantation rate(7 weeks)
  • Ongoing pregnancy rate(12 weeks)

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Muhammad Fawzy

IVF Lab Director

Ibn Sina Hospital

研究点 (2)

Loading locations...

相似试验